Skip to main content
. Author manuscript; available in PMC: 2021 Jan 15.
Published in final edited form as: Clin Cancer Res. 2020 Jan 14;26(14):3856–3867. doi: 10.1158/1078-0432.CCR-19-1397

Fig 6. Combination of venetoclax and AMG-176 in CLL cells.

Fig 6.

CLL lymphocytes from 5 patients were either vehicle (DMSO) treated or treated with 1, 5, 10, or 30 nM venetoclax (white bars), 100 and 300 nM AMG-176 (light grey bars) or combination of both (dark grey bars) for 24 h. (A - E) Samples from patient 133, 291, 963, 897, and 689 were treated and annexin/PI positivity was measured as described in the Methods section. DMSO value was subtracted from % cell death obtained after each treatment. Abbreviations used are A = AMG-176; V = venetoclax.